iSpecimen

iSpecimen Equity

The The Equity of iSpecimen (ISPC) as of Oct 22, 2026 is 3.09 M USD. In the previous year, The Equity was 3.31 M USD — a change of -6.73% (lower).

Equity

3.09 MUSD

YoY

-6.73%

Last updated:

In 2025, iSpecimen's equity was 3.09 M USD, a -6.73% increase from the 3.31 M USD equity in the previous year.

The iSpecimen Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
-18.42 M USD
Jan 1, 2019
-22.72 M USD
Jan 1, 2020
-27.28 M USD
Jan 1, 2021
29.79 M USD
Jan 1, 2022
20.31 M USD
Jan 1, 2023
9.74 M USD
Jan 1, 2024
3.31 M USD
Jan 1, 2025
3.09 M USD
The iSpecimen Equity history
YEAREquityYoY
3.09 MUSD-6.73%
3.31 MUSD-66.01%
9.74 MUSD-52.04%
20.31 MUSD-31.83%
29.79 MUSD-209.21%
-27.28 MUSD+20.07%
-22.72 MUSD+23.31%
-18.42 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

iSpecimen Stock analysis

What does iSpecimen do? iSpecimen, Inc. generates revenue through its iSpecimen Marketplace platform, which connects healthcare providers with biospecimens to researchers in biopharmaceutical, in vitro diagnostic (IVD), and government/academic sectors. The platform consolidates biospecimen procurement by offering a single online marketplace where healthcare supply partners provide de-identified healthcare data, enabling researchers to search, manage workflows, and access administrative tools. Biopharmaceutical companies, IVD firms, and academic institutions purchase access to the platform’s data and services to accelerate medical discovery and streamline procurement processes. The company’s functional areas—search, workflow, data, and administration and reporting—support these transactions through integrated administrative and compliance management for all users. The iSpecimen Marketplace platform serves biopharmaceutical companies, in vitro diagnostic (IVD) companies, and government/academic institutions by providing a centralized hub for biospecimen procurement. Healthcare providers supplying biospecimens use the platform to list their collections, while researchers from the target sectors access the data for their studies. The platform’s de-identified healthcare data, compiled from healthcare supply partners, is a key asset that drives transactions. Administrative and reporting functions within the platform streamline operations for both suppliers and researchers, reducing manual effort and improving compliance. iSpecimen, Inc. monetizes its platform by facilitating connections between biospecimen suppliers and researchers across biopharmaceutical, IVD, and academic sectors. The company’s revenue comes from transactions and services provided through the iSpecimen Marketplace, which includes search capabilities, workflow management, data access, and administrative support. Healthcare supply partners contribute de-identified healthcare data to the platform, which researchers use to identify and procure necessary biospecimens for medical research and development. iSpecimen is one of the most popular companies on Eulerpool.

Equity Details

Analyzing iSpecimen's Equity

iSpecimen's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding iSpecimen's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating iSpecimen's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

iSpecimen's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in iSpecimen’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about iSpecimen stock

The Equity of iSpecimen is 3.09 M USD in 2025.

The Equity of iSpecimen changed from 3.31 M USD to 3.09 M USD, representing a -6.73% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity iSpecimen since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's iSpecimen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — iSpecimen

All Key Metrics — iSpecimen